Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion

Robert G Maki; Jean-Yves Blay; George D Demetri; Jonathan A Fletcher; Heikki Joensuu; Javier Martín-Broto; Toshirou Nishida; Peter Reichardt; Patrick Schöffski; Jonathan C Trent

doi:10.1634/theoncologist.2014-0471

Back

Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion

Journal article

Open access

Peer reviewed

Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion

Robert G Maki, Jean-Yves Blay, George D Demetri, Jonathan A Fletcher, Heikki Joensuu, Javier Martín-Broto, Toshirou Nishida, Peter Reichardt, Patrick Schöffski and Jonathan C Trent

The oncologist (Dayton, Ohio), Vol.20(7), pp.823-830

2015-07

DOI: https://doi.org/10.1634/theoncologist.2014-0471

PMCID: PMC4492234

PMID: 26070915

Abstract

Gastrointestinal Stromal Tumors - therapy

Imatinib Mesylate - therapeutic use

Gastrointestinal Stromal Tumors - drug therapy

Gastrointestinal Stromal Tumors - pathology

Humans

Female

Male

Antineoplastic Agents - therapeutic use

Gastrointestinal Stromal Tumors - genetics

After the revelation of kinase targeting with orally available small molecules, the use of imatinib in chronic myelogenous leukemia and in gastrointestinal stromal tumor (GIST) has now become commonplace and just two of many examples of the use of kinase inhibitors in cancer. In this article, we discuss important practice points that may impact upon questions of therapy of primary and metastatic GIST, with the hope that the questions addressed in this rare solid tumor can serve as examples of what can be achieved with kinase-directed therapies in other cancers. We present cases that highlight some of the key issues in GIST management and afterward discuss both points of consensus and controversial issues in what is now recognized as one of the most common forms of sarcoma. The treatment of gastrointestinal stromal tumor (GIST) has become sophisticated with the availability of three approved agents in many countries and 15 years of experience with primary and metastatic disease. Important lessons from tyrosine-kinase inhibitors in GIST can be gleaned from this experience and will impact implementation of similar agents for other cancers.

Files and links (1)

url

https://doi.org/10.1634/theoncologist.2014-0471View

Published (Version of record) Open

Metrics

13 Record Views

22 Times Cited - Web of Science

See more details

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration; International collaboration
Citation topics: 1 Clinical & Life Sciences; 1.118 Soft Tissue, Bone & Nerve Cancers; 1.118.1520 Gastrointestinal Stromal Tumor
Web Of Science research areas: Oncology
ESI research areas: Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Details

Title: Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion
Creators: Robert G Maki - Tisch Cancer Institute, Mount Sinai Medical Center, New York, New York, USA; Department of Medical Oncology, Centre Léon Bérard, Lyon, France; Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA; Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Servicio de Oncología Médica, Fundación Instituto Valenciano de Oncología, Valencia, Spain; National Cancer Center Hospital East, Department of Surgery, Kashiwa, Japan; HELIOS Klinikum Berlin-Buch, Interdisciplinary Oncology, Berlin, Germany; General Medical Oncology, Leuven Cancer Institute, University Hospital Gasthuisberg, Catholic University Leuven, Leuven, Belgium; University of Miami Sylvester Cancer Center, Sarcoma Medical Oncology Program, Miami, Florida, USA bobmakimd@gmail.com
Jean-Yves Blay - Tisch Cancer Institute, Mount Sinai Medical Center, New York, New York, USA; Department of Medical Oncology, Centre Léon Bérard, Lyon, France; Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA; Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Servicio de Oncología Médica, Fundación Instituto Valenciano de Oncología, Valencia, Spain; National Cancer Center Hospital East, Department of Surgery, Kashiwa, Japan; HELIOS Klinikum Berlin-Buch, Interdisciplinary Oncology, Berlin, Germany; General Medical Oncology, Leuven Cancer Institute, University Hospital Gasthuisberg, Catholic University Leuven, Leuven, Belgium; University of Miami Sylvester Cancer Center, Sarcoma Medical Oncology Program, Miami, Florida, USA
George D Demetri - Tisch Cancer Institute, Mount Sinai Medical Center, New York, New York, USA; Department of Medical Oncology, Centre Léon Bérard, Lyon, France; Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA; Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Servicio de Oncología Médica, Fundación Instituto Valenciano de Oncología, Valencia, Spain; National Cancer Center Hospital East, Department of Surgery, Kashiwa, Japan; HELIOS Klinikum Berlin-Buch, Interdisciplinary Oncology, Berlin, Germany; General Medical Oncology, Leuven Cancer Institute, University Hospital Gasthuisberg, Catholic University Leuven, Leuven, Belgium; University of Miami Sylvester Cancer Center, Sarcoma Medical Oncology Program, Miami, Florida, USA
Jonathan A Fletcher - Tisch Cancer Institute, Mount Sinai Medical Center, New York, New York, USA; Department of Medical Oncology, Centre Léon Bérard, Lyon, France; Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA; Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Servicio de Oncología Médica, Fundación Instituto Valenciano de Oncología, Valencia, Spain; National Cancer Center Hospital East, Department of Surgery, Kashiwa, Japan; HELIOS Klinikum Berlin-Buch, Interdisciplinary Oncology, Berlin, Germany; General Medical Oncology, Leuven Cancer Institute, University Hospital Gasthuisberg, Catholic University Leuven, Leuven, Belgium; University of Miami Sylvester Cancer Center, Sarcoma Medical Oncology Program, Miami, Florida, USA
Heikki Joensuu - Tisch Cancer Institute, Mount Sinai Medical Center, New York, New York, USA; Department of Medical Oncology, Centre Léon Bérard, Lyon, France; Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA; Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Servicio de Oncología Médica, Fundación Instituto Valenciano de Oncología, Valencia, Spain; National Cancer Center Hospital East, Department of Surgery, Kashiwa, Japan; HELIOS Klinikum Berlin-Buch, Interdisciplinary Oncology, Berlin, Germany; General Medical Oncology, Leuven Cancer Institute, University Hospital Gasthuisberg, Catholic University Leuven, Leuven, Belgium; University of Miami Sylvester Cancer Center, Sarcoma Medical Oncology Program, Miami, Florida, USA
Javier Martín-Broto - Tisch Cancer Institute, Mount Sinai Medical Center, New York, New York, USA; Department of Medical Oncology, Centre Léon Bérard, Lyon, France; Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA; Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Servicio de Oncología Médica, Fundación Instituto Valenciano de Oncología, Valencia, Spain; National Cancer Center Hospital East, Department of Surgery, Kashiwa, Japan; HELIOS Klinikum Berlin-Buch, Interdisciplinary Oncology, Berlin, Germany; General Medical Oncology, Leuven Cancer Institute, University Hospital Gasthuisberg, Catholic University Leuven, Leuven, Belgium; University of Miami Sylvester Cancer Center, Sarcoma Medical Oncology Program, Miami, Florida, USA
Toshirou Nishida - Tisch Cancer Institute, Mount Sinai Medical Center, New York, New York, USA; Department of Medical Oncology, Centre Léon Bérard, Lyon, France; Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA; Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Servicio de Oncología Médica, Fundación Instituto Valenciano de Oncología, Valencia, Spain; National Cancer Center Hospital East, Department of Surgery, Kashiwa, Japan; HELIOS Klinikum Berlin-Buch, Interdisciplinary Oncology, Berlin, Germany; General Medical Oncology, Leuven Cancer Institute, University Hospital Gasthuisberg, Catholic University Leuven, Leuven, Belgium; University of Miami Sylvester Cancer Center, Sarcoma Medical Oncology Program, Miami, Florida, USA
Peter Reichardt - Tisch Cancer Institute, Mount Sinai Medical Center, New York, New York, USA; Department of Medical Oncology, Centre Léon Bérard, Lyon, France; Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA; Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Servicio de Oncología Médica, Fundación Instituto Valenciano de Oncología, Valencia, Spain; National Cancer Center Hospital East, Department of Surgery, Kashiwa, Japan; HELIOS Klinikum Berlin-Buch, Interdisciplinary Oncology, Berlin, Germany; General Medical Oncology, Leuven Cancer Institute, University Hospital Gasthuisberg, Catholic University Leuven, Leuven, Belgium; University of Miami Sylvester Cancer Center, Sarcoma Medical Oncology Program, Miami, Florida, USA
Patrick Schöffski - Tisch Cancer Institute, Mount Sinai Medical Center, New York, New York, USA; Department of Medical Oncology, Centre Léon Bérard, Lyon, France; Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA; Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Servicio de Oncología Médica, Fundación Instituto Valenciano de Oncología, Valencia, Spain; National Cancer Center Hospital East, Department of Surgery, Kashiwa, Japan; HELIOS Klinikum Berlin-Buch, Interdisciplinary Oncology, Berlin, Germany; General Medical Oncology, Leuven Cancer Institute, University Hospital Gasthuisberg, Catholic University Leuven, Leuven, Belgium; University of Miami Sylvester Cancer Center, Sarcoma Medical Oncology Program, Miami, Florida, USA
Jonathan C Trent - Tisch Cancer Institute, Mount Sinai Medical Center, New York, New York, USA; Department of Medical Oncology, Centre Léon Bérard, Lyon, France; Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA; Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Servicio de Oncología Médica, Fundación Instituto Valenciano de Oncología, Valencia, Spain; National Cancer Center Hospital East, Department of Surgery, Kashiwa, Japan; HELIOS Klinikum Berlin-Buch, Interdisciplinary Oncology, Berlin, Germany; General Medical Oncology, Leuven Cancer Institute, University Hospital Gasthuisberg, Catholic University Leuven, Leuven, Belgium; University of Miami Sylvester Cancer Center, Sarcoma Medical Oncology Program, Miami, Florida, USA
Publication Details: The oncologist (Dayton, Ohio), Vol.20(7), pp.823-830
Publisher: United States
Grant note: P50 CA127003 / NCI NIH HHS
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
Language: English
Resource Type: Journal article
PMID: 26070915
PMCID: PMC4492234
Record Identifier: 991031577350902976